Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Nvidia Corp (NVDA) Price & Performance

Bristol-Myers Squibb CoTrade
Nvidia CorpTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Nvidia Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while Nvidia Corp trades at $223.77 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 40.6× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BMYNVDA
Market Cap
$129.94B$5.27T
Sector
HealthTechnology
52-Week High
$65.89$235.75
52-Week Low
$42.60$165.17
Enterprise Value
$163.92B$5.20T
Dividend Yield
3.96%0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

Nvidia Corp

NVIDIA (NVDA) trades at $217.56, down 2.86% over the past 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.87 exceeding the $1.76 estimate. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97% and robust cash flow from operations of $64.09B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $325.86.

The outlook for NVDA is favorable, supported by accelerating AI chip demand and a dominant market position. Key opportunities include sustained revenue growth and expanding profitability, while risks involve heightened competition, potential peak AI spending, and market volatility. The stock's current valuation metrics, such as a P/E of 33.31, reflect high growth expectations that must be met to justify further upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Nvidia Corp

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.

Read more on NVDA